Uterine cancer

Immatics Announces Full Year 2023 Financial Results and Corporate Update

Retrieved on: 
Thursday, March 21, 2024
Ovarian cancer, Head, Uterine cancer, GSK, Patient, Dendreon, Commercial, Cancer, Bristol Myers Squibb, Neoplasm, Melanoma, TCR, Therapy, Research, MAGEA4, Sarcoma, GMP, Safety, Pharmacokinetics, Amgen, QC, CDMO, Development, Prevalence, Half-life, RECIST, Senior, FDA, Lung cancer, Administration, Conference, Entrepreneurship, Bank, Corr, Messenger, Protein, Pharmacology, Uveal melanoma, Pharmaceutical industry

“Immatics kicked off 2024 with a successful capital raise, providing significant financial runway and additional momentum to advance our ongoing clinical cell therapy and bispecific trials,” said Harpreet Singh, Ph.D., CEO and Co-Founder of Immatics.

Key Points: 
  • “Immatics kicked off 2024 with a successful capital raise, providing significant financial runway and additional momentum to advance our ongoing clinical cell therapy and bispecific trials,” said Harpreet Singh, Ph.D., CEO and Co-Founder of Immatics.
  • For IMA203CD8 GEN2, Immatics cleared dose level 4a (DL4a, up to ~1.6x109 TCR-T cells) in December 2023, which is currently intended to be the target dose for further development.
  • A next data update for both Phase 1b cohorts with IMA203 GEN1 and IMA203CD8 GEN2 is planned for 2H 2024.
  • On September 11, 2023, Immatics announced a strategic multi-platform collaboration with Moderna, combining Immatics’ target and TCR platforms with Moderna’s cutting-edge mRNA technology.

The Inner Circle acknowledges Nana E. Tchabo, MD, FACOG as a Pinnacle Life Member

Retrieved on: 
Thursday, March 7, 2024
Theta, Overlook Medical Center, Woman, Professional, Inner circle, Doctor of Philosophy, Multimedia, MD, Georgetown University, Education, Immunotherapy, Pathology, Thomas Jefferson University, Uterine cancer, ABOG, Parent, Principal investigator, Radiation, National Cancer Institute, Women's studies, Gynecologic Oncology (journal), Health, FACOG, Oncology nursing, Brown University, Vaginal cancer, Ovarian cancer, Associate, Gestational trophoblastic disease, Women's health, Biology, Mount Sinai School, Estate (law), Delta Sigma, Research, Carol, Medication

CHESTER, N.J., March 7, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology.

Key Points: 
  • CHESTER, N.J., March 7, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology.
  • Dr. Tchabo pursued higher education at Brown University where she received a Bachelor of Science in Neuroscience and a minor in Women's Studies.
  • She then attended the Warren Alpert Brown University School of Medicine, where she was cited for academic excellence.
  • Dr. Tchabo currently works at Atlantic Women's Cancer Associates, a part of Atlantic Health System Morristown and Overlook Medical Centers.

BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer

Retrieved on: 
Thursday, December 21, 2023
Food, HER2, Breakthrough therapy, ASCO, Collection, FDA, ESGO, Mortality, Gene amplification, BNTX, Incidence, Endometrial cancer, BioNTech, Breakthrough, Fast track (FDA), Patient, Uterine cancer, Data, ADC, Pharmaceutical industry

The designation is based on encouraging topline data from a Phase 1/2 study ( NCT05150691 ) with BNT323/DB-1303 in patients with HER2-expressing advanced endometrial cancer.

Key Points: 
  • The designation is based on encouraging topline data from a Phase 1/2 study ( NCT05150691 ) with BNT323/DB-1303 in patients with HER2-expressing advanced endometrial cancer.
  • Endometrial or uterine cancer is the second most common gynecologic cancer globally, with over 400,000 cases occurring each year1,2 and both incidence and mortality are increasing3,4.
  • “The Breakthrough Therapy designation for BNT323/DB-1303 shows the potential of our ADC candidate to address current treatment challenges for patients with advanced HER2-expressing endometrial cancer who progressed under several lines of systemic therapy.
  • The BNT323/DB-1303 program received FDA Fast Track designation for the treatment of endometrial cancer in January 2023.

Immatics Announces Third Quarter 2023 Financial Results and Business Update

Retrieved on: 
Tuesday, November 14, 2023
Senior, Entrepreneurship, CRS, Peptide, Regenerative Medicine Advanced Therapy, Patient, Triple-negative breast cancer, Cell, Research, Pharmacology, Therapy, Conference, ORR, Neurotoxicity, Infrared spectroscopy correlation table, Cytokine release syndrome, Uveal melanoma, Bristol Myers Squibb, Safety, Head, Cancer, Administration, CD4, PRAME, Uterine cancer, Lung cancer, Melanoma, Ovarian cancer, Half-life, Development, SAB, BRAF, CD8, MAGEA4, Cytopenia, TCR, Protein, FDA, DLT, Messenger, Cmax, Toxic epidermal necrolysis, Sarcoma, CMC, Neoplasm, Vaccine, Medical imaging, Pharmaceutical industry, Cryptocurrency, Fine chemical, Drug, Moderna, NSCLC

“Immatics has had a strong quarter and made steady progress both in terms of the advancement of our clinical programs and in business development.

Key Points: 
  • “Immatics has had a strong quarter and made steady progress both in terms of the advancement of our clinical programs and in business development.
  • An update on the clinical development plan is expected in the first quarter of 2024.
  • An update on the clinical development plan is expected in the first quarter of 2024.
  • On September 11, Immatics announced a strategic multi-platform collaboration with Moderna, combining Immatics’ target and TCR platforms with Moderna’s cutting-edge mRNA technology.

The Inner Circle Acknowledges, Nana E. Tchabo, MD, FACOG as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology

Retrieved on: 
Monday, November 13, 2023
Theta, Inner circle, Georgetown University, Brown University, Woman, Oncology nursing, Associate, Reproductive Sciences, Research, Radiation, Cervical cancer, Gynecologic Oncology (journal), Overlook Medical Center, Pathology, National Cancer Institute, Roswell Park, Mount Sinai School, Women's studies, Multimedia, Professional, Fellow, Thomas Jefferson University, Vaginal cancer, Medication, Health, Alpert Medical School, Vulvar cancer, ABOG, Uterine cancer, Exceptional Women in Publishing, Ovarian cancer, MD, Japanese Cancer Association, FACOG, Delta Sigma, Women's health, Atlantic Women's Colleges Conference, Carol, Volunteering, Flexner Report, Estate (law), Biology, Education, Birth control, Science, Gynaecology, Medicine, Cancer, New York (magazine), Neuroscience, Obstetrics

CHESTER, N.J., Nov. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology.

Key Points: 
  • CHESTER, N.J., Nov. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology.
  • Dr. Tchabo pursued higher education at Brown University where she received a Bachelor of Science in Neuroscience, minoring in Women's Studies.
  • She then attended the Warren Alpert Medical School of Brown University for her medical degree, where she was cited for academic excellence.
  • Dr. Tchabo currently works at Atlantic Women's Cancer Associates, a part of Atlantic Health Systems Morristown and Overlook Medical Centers.

Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

Retrieved on: 
Wednesday, November 8, 2023
Patient, FDA, Research, Pharmacology, Uveal melanoma, Regenerative Medicine Advanced Therapy, Uterine cancer, NSCLC, International Congress on Tuberculosis, Corr, Cmax, Ovarian cancer, Nivolumab, Infrared spectroscopy correlation table, TCR, Appendix, CMC, Neurotoxicity, Lung, SD, DLT, Cytokine release syndrome, Melanoma, ORR, Cell therapy, Triple-negative breast cancer, CET, PRAME, Safety, CRS, Society, Melanoma Research, Diagnosis, Today, Cytopenia, BRAF, Pharmaceutical industry, Vaccine, Medical imaging, MD

The update is focused on IMA203 GEN1 in melanoma at the recently defined recommended Phase 2 dose (RP2D) and the first clinical data for IMA203CD8 GEN2.

Key Points: 
  • The update is focused on IMA203 GEN1 in melanoma at the recently defined recommended Phase 2 dose (RP2D) and the first clinical data for IMA203CD8 GEN2.
  • In line with previous results, IMA203 GEN1 monotherapy was well tolerated at total doses up to 10x109 TCR-T cells infused.
  • The presentation is available on Immatics’ website – covering the complete data set including Phase 1a, Phase 1b Cohort A and the deprioritized Cohort B (IMA203 GEN1 combined with nivolumab).
  • Discussions with FDA to align on patient populations, trial design and CMC aspects concerning the planned Phase 2 trial are ongoing.

LUMINELLE Announces China National Intellectual Property Administration’s Decision to Grant Issuance of Patent for LUMINELLE Bx (Biopsy) System, Expanding Global Footprint

Retrieved on: 
Thursday, October 5, 2023
Oncology, Medical Devices, Health, Consumer, Women, Biotechnology, Patent, Cancer, Food, China National Intellectual Property Administration, American Society of Clinical Oncology, CNIPA, Death, Mortality, Disease, Uterine cancer, Anesthesia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Chinese patent medicine, Woman, Medical imaging, Biopsy

LUMINELLE (UVision360, Inc.), an innovative medical device company, announces today that the China National Intellectual Property Administration (CNIPA) has issued Chinese Patent No.

Key Points: 
  • LUMINELLE (UVision360, Inc.), an innovative medical device company, announces today that the China National Intellectual Property Administration (CNIPA) has issued Chinese Patent No.
  • 201880086268.8 titled “Biopsy Device and Method” for the LUMINELLE Bx System.
  • Issued on September 22, 2023, the new patent provides LUMINELLE with international intellectual property rights and allows the company to expand its technological footprint beyond the U.S. borders.
  • “The patent issuance from the CNIPA is a significant milestone for LUMINELLE as we continue to develop life-changing diagnostics for women everywhere,” said LUMINELLE CEO Allison London Brown.

Global Oncology Devices Research Report 2023: Enhanced Treatment Options Propels Growth - Analysis by Device Type (Ablation, Embolization), & Cancer Type (Breast, Uterine, Colon and Rectum, Prostate) - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 31, 2023
Health, Oncology, Medical Devices, Research report, Surgery, Value, Breast cancer, Radiation, Cancer, Ageing, Prostate, Ablation, USD, Incidence, Uterine cancer, Colon, Patient, Application, Prostate cancer, SCSI Peripheral Device Type, Protocol on Mines, Booby-Traps and Other Devices, PET/CT, Disease, Diagnosis, Mortality, Biopsy, Medical imaging, Speciality chemicals, Rectum, Embolization, Select, Breast

The Global Oncology Devices Market is expected to generate 217.00 billion by the end of 2029, up from USD 69.80 Billion in 2022.

Key Points: 
  • The Global Oncology Devices Market is expected to generate 217.00 billion by the end of 2029, up from USD 69.80 Billion in 2022.
  • During the forecast period, 2024-2029, the Global Oncology Devices market is expected to grow at a CAGR of 18.05%.
  • The oncology devices market is comprised of a vast assortment of medical devices used for the detection, treatment, and management of cancer.
  • PET/CT price in Select countries, In EUR
    Global Oncology Devices Market Segmentation: By Device Type
    Global Oncology Devices Market Size, By Ablation Devices, By Value, 2019H-2029F (USD Billion & CAGR)
    Global Oncology Devices Market Size, By Embolization devices, By Value, 2019H-2029F (USD Billion & CAGR)
    Global Oncology Devices Market Size, By Other Devices, By Value, 2019H-2029F (USD Billion & CAGR)
    Global Oncology Devices Market Segmentation: By Cancer Type
    Global Oncology Devices Market Size, By Breast cancer, By Value, 2019H-2029F (USD Billion & CAGR)
    Global Oncology Devices Market Size, By Uterine cancer, By Value, 2019H-2029F (USD Billion & CAGR)
    Global Oncology Devices Market Size, By Colon and rectum cancer, By Value, 2019H-2029F (USD Billion & CAGR)
    Global Oncology Devices Market Size, By Prostate cancer, By Value, 2019H-2029F (USD Billion & CAGR)
    Global Oncology Devices Market Size, By Other Cancer Types, By Value, 2019H-2029F (USD Billion & CAGR)
    Global Oncology Devices Market Segmentation: By Application
    Global Oncology Devices Market Size, By Chemotherapy, By Value, 2019H-2029F (USD Billion & CAGR)
    Global Oncology Devices Market Size, By Radiation, By Value, 2019H-2029F (USD Billion & CAGR)
    Global Oncology Devices Market Size, By Surgical, By Value, 2019H-2029F (USD Billion & CAGR)
    Global Oncology Devices Market Size, By Diagnosis, By Value, 2019H-2029F (USD Billion & CAGR)

NCCN Releases New Resource to Help Families Understand Pediatric Hodgkin Lymphoma, Part of Award-Winning Patient Information Series

Retrieved on: 
Tuesday, August 22, 2023
CLL, Hodgkin lymphoma, Uncertainty, ICIS, Leukemia & Lymphoma Society, Book, Policy, Survival, Bone marrow, Cancer, St. Jude Children's Research Hospital, Uterine cancer, Breast, Medicine, Bronze Award, Silver Award, LLS, Lung, Journal of the National Comprehensive Cancer Network, Colon, NCCN, Organization, Vomiting, CAR, AML, Estate (law), Digital health, Prostate Cancer Foundation of Australia, Amazon (company), Child, Gold Award, Effectiveness, Nausea, Hospital, Patient, Digital, Chronic lymphocytic leukemia, Acute myeloid leukemia, Caregiver, Chair, Disease, Dentistry, Nursing, Medical device, Medical imaging, MD

PLYMOUTH MEETING, Pa., Aug. 22, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) today announced the publication of NCCN Guidelines for Patients®: Hodgkin Lymphoma in Children. The book offers a comprehensive analysis of the treatment options, benefits, and risks of care approaches for pediatric Hodgkin lymphoma, one of the most curable forms of childhood cancer, with long-term survival rates of 90% or higher.1

Key Points: 
  • PLYMOUTH MEETING, Pa., Aug. 22, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) today announced the publication of NCCN Guidelines for Patients®: Hodgkin Lymphoma in Children .
  • NCCN Guidelines for Patients are based on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) used by healthcare providers all over the world as a guide to best practices in cancer care.
  • The NCCN Guidelines for Patients contain the same treatment information as the NCCN Guidelines but are written for people with cancer and their caregivers.
  • An independent study found the NCCN Guidelines for Patients to be among the most trustworthy resources for people seeking online information about cancer.

Immatics Announces Second Quarter 2023 Financial Results and Business Update

Retrieved on: 
Thursday, August 17, 2023
Synovial sarcoma, MAGEA4, Paul Ehrlich Institute, Prevalence, Half-life, CRS, DL, Cohort, Clinical trial, Lung cancer, BRAF, Uveal melanoma, CTA, Head, Bristol Myers Squibb, Research, Cohort study, PRAME, TCR, Development, State Administrative Expenses, Sarcoma, ATM, Protein, Cytokine release syndrome, Patient, PEI, Administration, Melanoma, Corr, Entrepreneurship, Uterine cancer, Toxic shock syndrome toxin-1, Ovarian cancer, ORR, Safety, Breast cancer, Nivolumab, Pharmaceutical industry, Vaccine, Medical imaging, Cryptocurrency

“Beyond our recent IMA203 updates, we are pleased to report that we closed the second quarter with a cash position funding operations into late 2025.

Key Points: 
  • “Beyond our recent IMA203 updates, we are pleased to report that we closed the second quarter with a cash position funding operations into late 2025.
  • As per the latest data cut-off of April 4, 2023, ACTengine® IMA203 TCR-T monotherapy Cohort A showed a 67% confirmed objective response rate (cORR) in an interim clinical update announced on May 2, 2023.
  • Next update on Immatics’ IMA203 Phase 1b cohorts, including the projected clinical development path for PRAME-targeted TCR-T monotherapy towards registration-directed trials is planned for 4Q 2023.
  • TCER® IMA402 (PRAME) – Immatics submitted a clinical trial application (CTA2) to the Paul-Ehrlich-Institute (PEI) in April 2023.